Share
Journal Information
Most often read
359
“Methodological notes”: a new and important section in Clínica e Investigación en ArteriosclerosisJosep Ribalta, Carlos Lahoz, Xavier Pintó
Clin Investig Arterioscler. 2023;35:243
359
Full text access
Open Article
223
Absence of the influence of the APOE gene on the incidence of type 2 diabetes mellitus in a cohort of workers: Effect of diet and shift workRocío Mateo-Gallego, Sofía Pérez-Calahorra, Ana M. Bea, Irene Gracia-Rubio, Carmen Rodrigo-Carbo, Belen Moreno-Franco, Fernando Civeira, Martín Laclaustra, Itziar Lamiquiz-Moneo
Clin Investig Arterioscler. 2023;35:226-35
223
181
Dietary modulation of advanced glycation end products metabolism on carotid intima-media thickness in type 2 diabetes patients: From the CORDIOPREV studyElena M. Yubero-Serrano, Francisco M. Gutiérrez-Mariscal, Purificación Gómez-Luna, Juan F. Alcalá-Diaz, Pablo Pérez-Martinez, José López-Miranda
Clin Investig Arterioscler. 2023;35:105-14
181
Open Article
143
Health-related lifestyle assessment among Spanish adults from 22 to 72 yearsPedro Luis Rodríguez García, Juan José Pérez Soto, Eliseo García Cantó, Marcos Meseguer Zafra, Raúl Salmerón Ríos, Pedro Juan Tárraga López
Clin Investig Arterioscler. 2023;35:12-20
143
Open Article
132
Clonal hematopoiesis and atherosclerotic cardiovascular disease: A primerMaría A. Zuriaga, José J. Fuster
Clin Investig Arterioscler. 2023;35:35-41
132
Open Article
105
Vascular smooth muscle cell phenotype is modulated by ligands of the lymphotoxin β receptor and the tumor necrosis factor receptorSusana Martín-Vañó, Alejandra Miralles-Abella, Pascual Castaño, Gema Hurtado-Genovés, María Aguilar-Ballester, Andrea Herrero-Cervera, Angela Vinué, Sergio Martínez-Hervás, Herminia González-Navarro
Clin Investig Arterioscler. 2023;35:1-11
105
Full text access
Open Article
87
Vascular smooth muscle cell aging: Insights from Hutchinson-Gilford progeria syndromeMagda R. Hamczyk, Rosa M. Nevado
Clin Investig Arterioscler. 2023;35:42-51
87
Open Article
81
Prevalence rates of chronic kidney disease and its association with cardiometabolic factors and cardiovascular diseases. SIMETAP-CKD studyAntonio Ruiz-Garcia, Ezequiel Arranz-Martínez, Nerea Iturmendi-Martínez, Teresa Fernández-Vicente, Montserrat Rivera-Teijido, Juan Carlos García-Álvarez
Clin Investig Arterioscler. 2023;35:64-74
81
Open Article
76
Consensus document for lipid profile determination and reporting in Spanish clinical laboratoriesTeresa Arrobas Velilla, Carlos Guijarro, Raquel Campuzano Ruiz, Manuel Rodríguez Piñero, José Francisco Valderrama Marcos, Antonio Pérez Pérez, Manuel Antonio Botana López, Ana Morais López, ... en representación del Grupo Multidisciplinar de Trabajo de Lípidos y Riesgo Vascular
Clin Investig Arterioscler. 2023;35:91-100
76
Full text access
Open Article
68
Arterial ageing and atherosclerotic risk: new perspectivesVicente Lahera Juliá, Ana M. Lahera García
Clin Investig Arterioscler. 2023;35:32-4
68
Open Article
65
Geostatistical analysis from the clinical laboratory in cardiovascular prevention for primary careSalomón Martín Pérez, Teresa Arrobas Velilla, Juan Fabiani de la Iglesia, Ignacio Vázquez Rico, Gema Varo Sánchez, Antonio León-Justel
Clin Investig Arterioscler. 2023;35:75-84
65
Open Article
63
Eating frequency has an inverse correlation with adiposity measures and non-invasive arterial stiffness parameters in healthy adult peopleSajjad Arefinia, Lida Jarahi, Hamed Khedmatgozar, Saeed Eslami Hasan Abadi, Mohammad Reza Shadmand Foumani Moghadam, André Tchernof, Hosein Soleimaninia, Reza Rezvani
Clin Investig Arterioscler. 2023;35:21-31
63
Open Article
52
Association of rs662799 and rs5070 genetic polymorphisms with hypertriglyceridemia and atherogenic dyslipidemia in pediatric patients in Southeast MexicoValeria Ovando Gómez, Soraya Amalí Zavaleta Muñiz, Héctor Ochoa-Díaz-López, José Armando Camilo Hernández Contreras, Cesar Antonio Irecta Nájera
Clin Investig Arterioscler. 2023;35:53-63
52
Open Article
49
Nutrition, cardiovascular disease risk and climate changeCarlos A. González Svatetz
Clin Investig Arterioscler. 2023;35:101-3
49
Full text access
Open Article
34
Evolocumab como tratamiento de la dislipemia secundaria a lorlatinibLaura Pérez Alonso, Raquel Cervera Calero, María Ángeles Campos Fernández de Sevilla, Miguel Ángel Moreno Palanco, Jorge Francisco Gómez Cerezo
Clin Investig Arterioscler. 2023;35:88-90
34
Open Article
29
A step forward in the consensus on lipid profile characteristics for cardiovascular preventionXavier Pintó, Juan Pedro-Botet
Clin Investig Arterioscler. 2023;35:85-7
29
Open Article
25
Observational study of patients from a Lipid Unit on lipid-modifying therapy for primary and secondary prevention: ULFI StudyÀlex Vila, Estel Pons, Patricia Trinidad García, Daniel Vidal, Sara López, Armand Grau
Clin Investig Arterioscler. 2023;35:272-9
25
Full text access
Open Article
25
Long-term treatment persistence and maintained reduction of LDL-cholesterol levels with evolocumab over 30 months: Results from the Spanish cohort of the European prospective HEYMANS studyAgustín Blanco Echevarría, Juan De Dios García Díaz, Assumpta Caixas, Núria Plana Gil, Miguel Ángel Rico Corral, Ian Bridges, Nafeesa Dhalwani, Sònia Gatell Menchen, Kausik K. Ray
Clin Investig Arterioscler. 2023;35:263-71
25
Full text access
Open Article
11
Pemafibrate: PROMINENT failure or an urgent need for therapeutic replacement?Juan Carlos Laguna Egea, Núria Roglans Ribas, Roger Bentanachs Raset
Clin Investig Arterioscler. 2023;35:202-5
11
Full text access
Open Article
8
Nutritional recommendations in the prevention and treatment of atherogenic dyslipidemiaVicente Pascual, José Luis Díaz, Jesús Millán Nuñez-Cortés, Pablo Pérez-Martínez
Clin Investig Arterioscler. 2023;35:155-63
8
Open Article